My research is focused on discovering and understanding metabolomics and epigenomics changes in hematology and hematologic malignancies, aiming to translating my findings into clinical usage. My early research experience offered me broad knowledge in understanding the molecular mechanisms of cellular regulations on signaling, metabolism and post translational modifications. I am interested in discovering novel mechanisms related to interactions of cancer cells in tumor microenvironment and characterize the vulnerabilities of blood cancers and designing strategies for clinical treatments.

In my recent study, I identified the critical function of mitochondrial protein lysine de-acylase, SIRT3, in DLBCLs, and showed its important role to sustain lymphoma metabolism. We generated mitochondrial targeted SIRT3 inhibitors, which have great potential for DLBCL treatments. Currently, I am investigating the unique activity of nucleotide metabolism in DLBCLs and its functions in lymphomagenesis and treatment.